Category Archives: Stem Cell Treatment


Sarah Ferguson was in pain during Eugenies wedding – and needed treatment to recover – Express

The Duchess of York, affectionately known as Fergie by the British public, decided to have pioneering regenerative stem cell therapy to be able to wear heels again. Fergie had to give up on her stilettos for a long time due to the excruciating pain she felt every time she tried to walk in them. And if she forced herself to wear high heels to mark important occasions she had to endure pain throughout the whole day.

Her feet caused Fergie trouble even during Princess Eugenies wedding last October.

Speaking to the Daily Mail, the Duchess of York said her feet were in such pain she felt relieved to be able to sit down in the pew and rest them for a while before Eugenie entered St Georges Chapel.

The source of the pain seemed to be her big toe, and now, thanks to regenerative stem cell therapy the Duchess is no longer in pain every time she opts to wear shows other than flats.

Fergie headed to the Bahamas to undergo stem cell therapy - an alternative to surgery which is yet to be proven fully safe and effective on humans and is therefore not widely available in the UK.

Speaking about her trip, she said: I went to the Bahamas in March to have the treatment.

I think my toes were ruined by all the riding I did when I was young.

They shaved the bone here and implanted stem cells 20 million of them taken from my midriff into my feet to make new cartilage.

It takes about six months to heal but now I can walk in heels!

READ MORE:The touching reason Beatrice will have British wedding

Fergie underwent a series of treatments during the years, including vitamin injections, organic fillers and botox - which she had a long time ago, when there was nothing else available.

Ahead of Eugenies wedding, Fergie underwent laser treatment to look her best.

Fergie attributed her glowing skin on October 12, the day of Princess Eugenies wedding, to her happiness.

But she also revealed she did seek the help of a professional to improve her natural beauty.

She said: The happiness was shining out of me because my daughter was getting married.

DON'T MISS

I was so glad. I love Jack. When Im passionate about anything, my eyes shine.

Above all, it was being joyful for Eugenie that made me look good.

But Id had some laser treatment on my face which helped, too.

Despite having used several techniques to stave off ageing, Fergie said there is one she is no longer going to have - Botox.

She said: I had Botox a long time ago when there was nothing else available.

I really dont like the frozen look.

Im so animated and I like to be myself.

I dont like the thought of needles and am very glad if I look well and happy.

Fergie also said she has stopped sunbathing after suffering two losses in her life which helped her realise she must take care of her skin just as well as any other organs.

Read more:
Sarah Ferguson was in pain during Eugenies wedding - and needed treatment to recover - Express

Drexel on the Road: Stem cell study for osteoarthritis – WKRG News 5

PENSACOLA, Fla. (WKRG) Osteoarthritis affects millions of people in the US. Symptoms range from minor pain to crippling pain that compromises quality of life. A groundbreaking study is underway at four prestigious research facilities in the United States. One of those is right here on the Gulf Coast. Tonight, Drexel Gilbert is on the road in Gulf Breeze.

Lori Jamison is a Pensacola native who, as a teenager, played basketball at Pine Forest High School. Today, she suffers from osteoarthritis in her knee. She believes its a result of basketball injuries.

I get stiffness, it interferes with my mobility. Sometimes its like a sharp needle going down your leg. When I go to the movie theater, I have to sit on the back row so I can stretch it out, Jamison said. She is participating in a clinical trial at Andrews Research and Education Foundation in Gulf Breeze.

The research is studying stem cell treatment for osteoarthritis in the knee. AREF is one of only four facilities in the country participating in the study. The others are Emory Orthopedics & Spine Center, Duke University and Sanford Health. Researchers hope it leads to FDA approval for the treatment. If that happens, it could be life-changing for patients.

Hopefully reduce their pain if not actually get rid of their pain. That is our goal. We want to delay, if not prevent, total knee replacement, said Dr. Josh Hackel, who is the primary investigator for the Andrews phase of the study. Were comparing three different stem cell sources. Bone marrow from their pelvis, adipose- thats tissue from their belly fat- and the third is umbilical cord tissue donated from pregnant mothers.

The bone marrow and belly fat stem cells are harvested from the study participants, under local anesthesia. The stem cells are later implanted into the knee joint using ultrasound guidance to implant the cells into the knee joint.

Jamison has already undergone stem cell harvesting.

It was very easy, very convenient, no downtime after the procedure was done, Jamison said

This $13 million clinical trial is being funded entirely by a grant from Bernie Marcus, founder of the Marcus Foundation and co-founder of Home Depot. Osteoarthritis is an issue that is close to the philanthropists heart because his mother was left disabled by the illness at a young age.

There will be around 120 participants at each of the four sites. There are plenty of openings. If youd like to be considered for the study, call AREF at 850-916-8591.

Read more here:
Drexel on the Road: Stem cell study for osteoarthritis - WKRG News 5

Jazz plays itself into cell therapy – Vantage

Approval of the first Car-T therapy, Novartiss Kymriah, brought with it a concomitant green light for Roches rheumatoid arthritis drug Actemra for treating cytokine release syndrome (CRS), a frequent side effect of Car-T. Now Jazz Pharmaceuticals wants in on the act, starting a 35-subject study of its drug Defitelio to treat the side effect of neurotoxicity associated with Gileads Car-T therapy Yescarta. Defitelio is approved for treating a rare complication of stem cell transplantation, and the thinking is that its mechanism of cathepsin G inhibition could help prevent endothelial cell damage, protecting the CNS and minimising neurotoxicity. Little is known about why some Car-T patients experience neurotoxicity, but this is thought to be related to CRS. The logic behind Actemras useis that the drug blocks IL-6, one of the most highly elevated cytokines in CRS. Advantages for Defitelio could be arguable safety while its label cites haemorrhage risk it does not have Actemras boxed warning over infections and slightly longer patent life. Still, as Defitelio is a small molecule it might end up being genericised before the US sees biosimilar versions of Actemra.

More here:
Jazz plays itself into cell therapy - Vantage

Gnaw on the Remake of David Cronenberg’s ‘Rabid’ This December [Trailer] – Bloody Disgusting

Ahead of its U.S. Premiere at Screamfest next week (Oct. 15), Scream Factory! has announced a release date forJenandSylvia SoskasRabid, their remake of the 1977 film from David Cronenberg.

While we really would have enjoyed an October release for Rabid, the film will open in theaters and on VOD platforms Friday the 13th of December.

Meagan reviewed Rabid, calling it a love letter to Cronenberg and Canada, further adding that the gore and makeup effects are worth the price of admission, and so is this new iteration of Rose.

Heres a brand new trailer.

In the film, After aspiring fashion designer Rose (Laura Vandervoort) suffers a disfiguring traffic accident she undergoes a radical and untested stem-cell treatment. The experimental transformation is a miraculous success, transforming her into a ravishing beauty. But she soon develops an uncontrollable sexual appetite, resulting in several torrid encounters, which sees her lovers become rabid carriers of death and disease. As the illness mutates and the contagion spreads out of control, all hell breaks loose as the infected rampage through the city on a violent and gruesome killing spree.

Ben Hollingsworthalso stars as Brad, a fashion photographer withHanneke Talbot(Playing Dead) portraying Roses best friend Chelsea; andMackenzie Gray(Legion, Riverdale) is arrogant fashion designer Gunter.Rabidwill also feature WWE superstarsCM Punkas Billy and his wife, New York Times best-selling authorAJ Mendezas Kira.

View original post here:
Gnaw on the Remake of David Cronenberg's 'Rabid' This December [Trailer] - Bloody Disgusting

Advanced Research Report on Animal Stem Cell Therapy Market 2019 Potentially Growing Significant Business Opportunities with top companies U.S. Stem…

Crystal Market Research authorities conduct a triangulated approach of primary and secondary research on Global Animal Stem Cell Therapy Market and carry out an in-depth analysis of multiple factors, including Animal Stem Cell Therapy technological developments and the demand-supply shifts in various markets across the globe to accurately forecast the industrys growth possibilities. To assist clients to frame effective tactics for growth on global Animal Stem Cell Therapy market for the period of 2019 to 2025.

It offers market insights from the statistics, gathered from reliable Animal Stem Cell Therapy market informants such as manufacturers, channel partners, decision makers, and regulatory bodies. Based on various clients stipulations, Animal Stem Cell Therapy also produces customized reports, which will help local vendors and global players cement their position in the chemicals and materials market.

Click Here for Get Sample Copy of this Report @https://www.crystalmarketresearch.com/report-sample/HC084561

The Animal Stem Cell Therapy market outline segment of the report investigates progression, for example, drivers, limitations, and opportunities that, at present, strongly affect the market and could impact the market in future also. Animal Stem Cell Therapy market share analysis has been given in the report with a particular ultimate objective to explain the power of contention between market players working over the globe.

Get it in discounted Price: https://www.crystalmarketresearch.com/check-discount/HC084561

Get Customized Research Report: https://www.crystalmarketresearch.com/customization/HC084561

Contacts Us:

Judy | 304 South Jones Blvd, Suite 1896

Las Vegas NV 89107

United States

E-mail: sales@crystalmarketresearch.com | Ph: +1-888-213-4282

The rest is here:
Advanced Research Report on Animal Stem Cell Therapy Market 2019 Potentially Growing Significant Business Opportunities with top companies U.S. Stem...

Stem Cell Therapy Market 2019: Prosperous Growth, Recent Trends and Demand by Top Key Vendors like Osiris Therapeutics, MEDIPOST Co., Anterogen Co.,…

Global Stem Cell Therapy Market Report assistances industry leaders to make confident capital investment decisions, develop strategic plans, optimize their business portfolio, innovate successfully and operate safely and sustainably. The report also offers a detailed summary of the industry including definitions, classifications, growth factors, applications and market chain structure, revenue development in terms of volume with respect to the Stem Cell Therapy market.

The report also embraces the absolute growth revenue value of the Stem Cell Therapy market across the globe over the forecast period 2019-2026. The Stem Cell Therapy Market is anticipated to surpass more than US$ xxx million by 2026 at a CAGR of xx% in the given forecast period.

Request Sample Copy of this Report @: https://www.qyreports.com/request-sample/?report-id=132668

Top Key Vendors:

Osiris Therapeutics, Inc. (U.S.), MEDIPOST Co., Ltd. (South Korea), Anterogen Co., Ltd. (South Korea), Pharmicell Co., Ltd. (South Korea), Holostem Terapie Avanzate S.r.l. (Italy).

Key reason to purchase Stem Cell Therapy Market report:

As the demand for new innovative solutions increases and more startups arise in the space which leads to growth and excessive demand for the Stem Cell Therapy Market in 2019 to 2025. This research report consists of the worlds crucial region market share, size (volume), trends including the product profit, price, Value, production, capacity, capability utilization, supply, and demand and industry growth rate.

Get 40% Discount on this Premium Report @: https://www.qyreports.com/request-sample/?report-id=132668

The market in Asia Pacific is expected to witness the fastest growth in the Global Stem Cell Therapy market over the forecast period. Recent and upcoming Global opportunities have been analyzed across several Global regions, such as North America, Latin America, Asia-Pacific, Europe, and India.

Finally, all aspects of the Global Stem Cell Therapy Market are quantitatively as well qualitatively assessed to study the Global as well as regional market comparatively. This market study presents essential information and accurate data about the market providing a complete statistical study of this market on the basis of market drivers, limitations and its future prospects. The report supplies the international economic competition with the assistance of Porters Five Forces Analysis and SWOT Analysis.

Table of Contents

Global Stem Cell Therapy Market Research Report

Chapter 1 Stem Cell Therapy Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Manufacture, Income (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Manufacture, Revenue (Price), Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Purchasers

Continue to TOC

For More Information: https://www.qyreports.com/enquiry-before-buying/?report-id=132668

About Us Qyreports:

We at, Qyreports, a leading market research report published accommodate more than 4,000 celebrated clients worldwide putting them at advantage in todays competitive world with our understanding of research. Our list of customers includes prestigious Chinese companies, multinational companies, SMEs and private equity firms whom we have helped grow and sustain with our fact-based research. Our business study covers a market size of over 30 industries offering unfailing insights into the analysis to reimagine your business. We specialize in forecasts needed for investing in a new project, to revolutionize your business, to become more customer centric and improve the quality of output.

Contact:

QYReports

Jones John

(Sales Manager)

204, Professional Centre,

7950 NW 53rd Street, Miami, Florida 33166

+(1) 786-292-8164

sales@qyreports.com

http://www.qyreports.com

See the article here:
Stem Cell Therapy Market 2019: Prosperous Growth, Recent Trends and Demand by Top Key Vendors like Osiris Therapeutics, MEDIPOST Co., Anterogen Co.,...

BEYOND LOCAL: Expert recommends ‘path of cautious optimism’ about the future of stem cell treatment – TimminsToday

This article, written byKatharine Sedivy-Haley, University of British Columbia, originally appeared on The Conversation and is republished here with permission:

When I was applying to graduate school in 2012, it felt like stem cells were about to revolutionize medicine.

Stem cells have the ability to renew themselves, and mature into specialized cells like heart or brain cells. This allows them to multiply and repair damage.

If stem cell genes are edited to fix defects causing diseases like anemia or immune deficiency, healthy cells can theoretically be reintroduced into a patient, thereby eliminating or preventing a disease. If these stem cells are taken or made from the patient themselves, they are a perfect genetic match for that individual, which means their body will not reject the tissue transplant.

Because of this potential, I was excited that my PhD project at the University of British Columbia gave me the opportunity to work with stem cells.

However, stem cell hype has led some to pay thousands of dollars on advertised stem cell treatments that promise to cure ailments from arthritis to Parkinsons disease. These treatments often dont help and may harm patients.

Despite the potential for stem cells to improve medicine, there are many challenges as they move from lab to clinic. In general, stem cell treatment requires we have a good understanding of stem cell types and how they mature. We also need stem cell culturing methods that will reliably produce large quantities of pure cells. And we need to figure out the correct cell dose and deliver it to the right part of the body.

Embryonic, 'induced and pluripotent

Stem cells come in multiple types. Embryonic stem cells come from embryos which makes them controversial to obtain.

A newly discovered stem cell type is the induced pluripotent stem cell. These cells are created by collecting adult cells, such as skin cells, and reprogramming them by inserting control genes which activate or induce a state similar to embryonic stem cells. This embryo-like state of having the versatile potential to turn into any adult cell type, is called being pluripotent.

However, induced pluripotent and embryonic stem cells can form tumours. Induced pluripotent stem cells carry a particularly high risk of harmful mutation and cancer because of their genetic instability and changes introduced during reprogramming.

Genetic damage could be avoided by using younger tissues such as umbilical cord blood, avoiding tissues that might contain pre-existing mutations (like sun-damaged skin cells), and using better methods for reprogramming.

Stem cells used to test drugs

For now, safety concerns mean pluripotent cells have barely made it to the clinic, but they have been used to test drugs.

For drug research, it is valuable yet often difficult to get research samples with specific disease-causing mutations; for example, brain cells from people with amyotrophic lateral sclerosis (ALS).

Researchers can, however, take a skin cell sample from a patient, create an induced pluripotent stem-cell line with their mutation and then make neurons out of those stem cells. This provides a renewable source of cells affected by the disease.

This approach could also be used for personalized medicine, testing how a particular patient will respond to different drugs for conditions like heart disease.

Vision loss from fat stem cells

Stem cells can also be found in adults. While embryonic stem cells can turn into any cell in the body, aside from rare newly discovered exceptions, adult stem cells mostly turn into a subset of mature adult cells.

For example, hematopoietic stem cells in blood and bone marrow can turn into any blood cell and are widely used in treating certain cancers and blood disorders.

A major challenge with adult stem cells is getting the right kind of stem cell in useful quantities. This is particularly difficult with eye and nerve cells. Most research is done with accessible stem cell types, like stem cells from fat.

Fat stem cells are also used in stem cell clinics without proper oversight or safety testing. Three patients experienced severe vision loss after having these cells injected into their eyes. There is little evidence that fat stem cells can turn into retinal cells.

Clinical complications

Currently, stem cell based treatments are still mostly experimental, and while some results are encouraging, several clinical trials have failed.

In the brain, despite progress in developing treatment for genetic disorders and spinal cord injury, treatments for stroke have been unsuccessful. Results might depend on method of stem cell delivery, timing of treatment and age and health of the patient. Frustratingly, older and sicker tissues may be more resistant to treatment.

For eye conditions, a treatment using adult stem cells to treat corneal injuries has recently been approved. A treatment for macular degeneration using cells derived from induced pluripotent stem cells is in progress, though it had to be redesigned due to concerns about cancer-causing mutations.

A path of cautious optimism

While scientists have good reason to be interested in stem cells, miracle cures are not right around the corner. There are many questions about how to implement treatments to provide benefit safely.

In some cases, advertised stem cell treatments may not actually use stem cells. Recent research suggests mesenchymal stem cells, which are commonly isolated from fat, are really a mixture of cells. These cells have regenerative properties, but may or may not include actual stem cells. Calling something a stem cell treatment is great marketing, but without regulation patients dont know what theyre getting.

Members of the public (and grad students) are advised to moderate their excitement in favour of cautious optimism.

Katharine Sedivy-Haley, PhD Candidate in Microbiology and Immunology, University of British Columbia

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Continue reading here:
BEYOND LOCAL: Expert recommends 'path of cautious optimism' about the future of stem cell treatment - TimminsToday

Golf: Brooks Koepka healthy again after stem cell treatment but game rusty – The Straits Times

LAS VEGAS (REUTERS) - Brooks Koepka is healthy again but his game was ailing as he shot a mediocre one-under 70 in his first start of the new PGA Tour season at the Shriners Hospitals for Children Open in Las Vegas on Thursday (Oct 3).

A day after revealing he had undergone stem cell treatment on a troublesome left knee, Koepka was far from his best at TPC Summerlin, trailing early Canadian leader Nick Taylor by seven strokes.

The 29-year-old world No. 1, whose rust was evident, ran up five birdies and four bogeys.

Koepka said stem cells were injected into his knee the day after the Tour Championship in late August.

"Finally feel 100 per cent, which is nice, and hopefully stay that way for the rest of the season," he said. "I'd been battling it there for the last four months of that season.

"My patella tendon was partially torn ... I also had a wrist injury."

Those concerns did not stop Koepka from a magnificent season in the Majors. He won the PGA Championship, was runner-up at the Masters and US Open, and fourth at the British Open.

Makes one wonder what he can do in 2020 if he can put in some time on the range.

"Last year I didn't practise at all," said the American. "I finally feel good enough where I can actually practise and feel prepared coming into golf tournaments. I'll be practising this year."

Koepka, an especially dangerous competitor when he has a chip on his shoulder, was controversially beaten for PGA Tour Player of the Year in a vote by his peers.

Never mind his Major record, Koepka was bested by season-long FedEx Cup winner Rory McIlroy. The tour did not reveal the vote totals.

Koepka shrugged off the snub, making a comparison with the NBA's dominant player of the past decade.

"LeBron (James) has only won four MVPs (most valuable player awards) and I'm pretty sure he's been the best player for more than just four years," Koepka said.

"I don't play for awards. I just play to win, win trophies, win tournaments."

While Koepka left some money on the table on Thursday, Canadian Taylor struck with six birdies, as well as an eagle at the short par-four 14th, where his 315-yard tee shot stopped five feet from the cup.

Taylor led by two strokes from a trio including veteran Phil Mickelson with half the field back in the clubhouse.

View post:
Golf: Brooks Koepka healthy again after stem cell treatment but game rusty - The Straits Times

New Viral Vector for Sickle Cell Gene Therapy Likely to Be More Effective, NIH Study Says – Sickle Cell Anemia News

A newly designed viral vector the vehicle that delivers a gene therapyto a patients cells for use insickle cell anemia is more efficient than earlier vectors at introducing healthy copies of genes into stem cells and can be produced in greater amounts, studies in animal models show.

The study Development of a forward-orientated therapeutic lentiviral vector for hemoglobin disorders was published in the journal Nature Communications.

Hemoglobin is the protein in red blood cells that binds oxygen, allowing oxygen to be transported around the body. Mutations in the HBBgene, which encodes a component of hemoglobin, causessickle cell.

Gene therapies involve either altering the mutated gene or introducing a healthy version of that gene to the body. Still under development for sickle cell, an estimated 27 patients have undergone experimental gene therapy. One strategy involves removing hematopoietic stem cells (which function to produce blood cells) from a patients bone marrow. A healthy copy of the HBB gene is then introduced into the cells using a modified, harmless virus known as a viral vector. The cells are then transplanted back into the patient where they will produce healthy red blood cells.

Traditionally, viral vectors for sickle cell have been designed in a way known as reverse structural orientation. This means that the HBB gene is translated or read from right to left, like reading an English sentence backwards. The reverse structural orientation design ensures that a key section of the gene (known as intron 2), which is necessary for the production of high levels of the HBB gene, is retained during viral vector preparation.

However, this design makes preparing the viral vectors more difficult, and decreases the efficiency of introducing the gene into the stem cells.

Researchersat the National Institutes of Healthdesigned a new viral vector, one in which the HBB gene is forward orientated and read from left to right. Genes essential for the virus were inserted into intron 2, meaning that only vectors that retained intron 2 would be produced (a type of positive selection).

Our new vector is an important breakthrough in the field of gene therapy for sickle cell disease, John Tisdale, MD, chief of the Cellular and Molecular Therapeutic Branch at the National Heart, Lung, and Blood Institute (NHLBI) and the studys senior author, said in a press release.

Its the new kid on the block and represents a substantial improvement in our ability to produce high capacity, high efficiency vectors for treating this devastating disorder, he added.

The researchers compared the new vectors to traditional reverse-orientated vectors in mouse and monkey models. The new vectors were four to 10 times more efficient at introducing the healthy HBBgene into the stem cells, and could carry up to six times more HBB genes compared to the conventional vectors.

Furthermore, the new vectors remained incorporated into the cells of monkeys up to four years after a transplant. These vectors could also be produced in greater amounts, which may lessen the time and costs required for large-scale vector production.

The researchers hope that these characteristics will make gene therapy for sickle cell disease more effective and increase its use. The new vector design still needs to be tested in clinical trials in patients.

Our lab has been working on improving beta-globin vectors for almost a decade and finally decided to try something radically different and it worked, Tisdale said.

These findings bring us closer to a curative gene therapy approach for hemoglobin disorders, he added.

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

Total Posts: 94

Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Tcnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.

Read more:
New Viral Vector for Sickle Cell Gene Therapy Likely to Be More Effective, NIH Study Says - Sickle Cell Anemia News

R3 Stem Cell Announces Addition of World Renowned Exosome Expert Dr. Ian White to Training Course – Yahoo Finance

The nation's leading regenerative training company, R3 Stem Cell, today announced the addition of world renowned Exosomes expert Dr. Ian White as a speaker at its training courses. He will be speaking at the October 18, 2019 course on Exosomes and there are still a few spots remaining!

LAS VEGAS, Oct. 10, 2019 /PRNewswire-PRWeb/ -- R3 Stem Cell announces it has added an exosome presentation to its upcoming regenerative training courses. The next course is October 18-19th, 2019 in Las Vegas with spots still open.

The speaker, Dr. Ian White PhD, is a world renowned expert on exosomes. He completed training at several Ivy League universities including Cornell, Harvard and Dartmouth. He currently serves as the Chief Scientific Officer at IMAC Regeneration Centers along with being President of Biofirma, which is a regenerative tissue manufacturing company.

Dr. White regular speaks worldwide on the topic of exosomes, stem cells and how they participate clinically to help optimize regenerative therapy outcomes. Exosome stem cell therapy is an amazing therapeutic option for patients, however, most providers do not understand the biologics and how to implement them properly.

According to R3 CEO David Greene, MD, MBA, "Obtaining knowledge on exosomes is important now, as patients are asking about them! Providers need to understand when to use them, how they work, and should have hands on experience with them. Our training course provides all of that experience."

R3 Stem Cell is the nation's leader in regenerative training, and provides a comprehensive education and hands on experience for providers to become their local leader. Along with offering the first rate exosome presentation, R3 will also have exosomes products on hand for attendees to try in a hands on setting.

Limited spots are still available for the upcoming October 18-19, 2019 training in Las Vegas. R3 is still offering $1000 off for the training, visit https://stemcelltrainingcourse.org/registration/ to sign up or call (844) GET-STEM.

Read the original:
R3 Stem Cell Announces Addition of World Renowned Exosome Expert Dr. Ian White to Training Course - Yahoo Finance